


CLAIMS

1. A compound of formula I



in a crystal form A that has a melting point, by Differential Scanning Calorimetry, of about 264°C with simultaneous decomposition, at a heating rate of 20° C/min and the following characteristic diffraction lines (2θ in angular degrees ± 0.2°) in the X-ray diffraction pattern thereof: 3.6°, 7.3°, 13.4°, 14.6°, 18.3°, 22.0°, 25.8°, 25.9°, 29.5°; or

in a crystal form B that has a melting point, by Differential Scanning Calorimetry, of about 270°C with simultaneous decomposition, at a heating rate of 20° C/min and the following characteristic diffraction lines (2θ in angular degrees ± 0.2°) in the X-ray diffraction pattern thereof: 7.2°, 9.3°, 12.0°, 12.8°, 13.1°, 14.5°, 17.4°, 20.4°, 23.2° and 25.8°.

2. A pharmaceutical composition comprising, as active ingredient, an effective amount of the compound of formula I in crystal form A or B as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
3. A composition according to claim 2, which is in inhalable form.
4. The use of a compound according to claim 1 in crystal form A or B for the preparation of a medicament for the treatment of an inflammatory or obstructive airways disease.
5. A method of preparing a compound of formula I in crystal form A as defined in claim 1 which comprises crystallising the compound of formula I as defined in claim 1 from a solution thereof in isopropanol, ethyl acetate, n-butanol, hexane, heptane, tert-butylmethylether, toluene or tetrahydrofuran.

6. A method of preparing a compound of formula I in crystal form B as defined in claim 1 which comprises crystallising the compound of formula I as defined in claim 1 from a solution thereof in ethanol, methanol or methylene chloride.
7. A crystal form of the compound of formula I, substantially as herein described with reference to any of the Examples.
8. A crystal form of the compound of formula I, substantially as herein described with reference to either of the drawings.